BEACHBODY CO INC/THE (BODI) Stock Fundamental Analysis
NYSE:BODI - New York Stock Exchange, Inc. - US0734633094 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to BODI. BODI was compared to 72 industry peers in the Diversified Consumer Services industry. While BODI seems to be doing ok healthwise, there are quite some concerns on its profitability. BODI is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BODI had negative earnings in the past year.
BODI had a negative operating cash flow in the past year.
In the past 5 years BODI always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: BODI reported negative operating cash flow in multiple years.
1.2 Ratios
BODI's Return On Assets of -41.41% is on the low side compared to the rest of the industry. BODI is outperformed by 80.56% of its industry peers.
BODI has a worse Return On Equity (-262.84%) than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.41% | ||
| ROE | -262.84% | ||
| ROIC | N/A |
ROA(3y)-46.66%
ROA(5y)-36.36%
ROE(3y)-176.86%
ROE(5y)-122.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BODI's Gross Margin of 69.42% is amongst the best of the industry. BODI outperforms 86.11% of its industry peers.
In the last couple of years the Gross Margin of BODI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BODI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.22%
GM growth 5Y-1.01%
2. Health
2.1 Basic Checks
BODI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BODI has been increased compared to 1 year ago.
The number of shares outstanding for BODI has been reduced compared to 5 years ago.
The debt/assets ratio for BODI is higher compared to a year ago.
2.2 Solvency
BODI has an Altman-Z score of -4.55. This is a bad value and indicates that BODI is not financially healthy and even has some risk of bankruptcy.
BODI's Altman-Z score of -4.55 is on the low side compared to the rest of the industry. BODI is outperformed by 76.39% of its industry peers.
There is no outstanding debt for BODI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.55 |
ROIC/WACCN/A
WACC11.29%
2.3 Liquidity
BODI has a Current Ratio of 0.52. This is a bad value and indicates that BODI is not financially healthy enough and could expect problems in meeting its short term obligations.
BODI has a worse Current ratio (0.52) than 75.00% of its industry peers.
BODI has a Quick Ratio of 0.52. This is a bad value and indicates that BODI is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of BODI (0.41) is worse than 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.52 | ||
| Quick Ratio | 0.41 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 46.06% over the past year.
BODI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -26.11%.
The Revenue for BODI have been decreasing by -11.14% on average. This is quite bad
EPS 1Y (TTM)46.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.62%
Revenue 1Y (TTM)-26.11%
Revenue growth 3Y-21.74%
Revenue growth 5Y-11.14%
Sales Q2Q%-39.72%
3.2 Future
The Earnings Per Share is expected to grow by 24.47% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -25.18% on average over the next years. This is quite bad
EPS Next Y57.44%
EPS Next 2Y24.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-41.79%
Revenue Next 2Y-25.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BODI. In the last year negative earnings were reported.
Also next year BODI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BODI is valued cheaper than 98.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2.8 |
4.3 Compensation for Growth
A more expensive valuation may be justified as BODI's earnings are expected to grow with 24.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.47%
EPS Next 3YN/A
5. Dividend
5.1 Amount
BODI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BODI (7/23/2025, 11:38:14 AM)
4.5541
+0.33 (+7.92%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)
Earnings (Next)
Inst Owners40.75%
Inst Owner ChangeN/A
Ins Owners5.21%
Ins Owner Change7.45%
Market Cap31.92M
Analysts80
Price Target10.54 (131.44%)
Short Float %6.62%
Short Ratio4.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.24%
Min EPS beat(2)-77.42%
Max EPS beat(2)42.94%
EPS beat(4)3
Avg EPS beat(4)9.88%
Min EPS beat(4)-77.42%
Max EPS beat(4)51.05%
EPS beat(8)4
Avg EPS beat(8)-4.53%
EPS beat(12)5
Avg EPS beat(12)-9.36%
EPS beat(16)8
Avg EPS beat(16)-7.94%
Revenue beat(2)2
Avg Revenue beat(2)7.92%
Min Revenue beat(2)5.31%
Max Revenue beat(2)10.54%
Revenue beat(4)2
Avg Revenue beat(4)2.63%
Min Revenue beat(4)-2.88%
Max Revenue beat(4)10.54%
Revenue beat(8)4
Avg Revenue beat(8)2.03%
Revenue beat(12)6
Avg Revenue beat(12)1.32%
Revenue beat(16)8
Avg Revenue beat(16)1.01%
PT rev (1m)0.08%
PT rev (3m)-16.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.2%
EPS NY rev (1m)0%
EPS NY rev (3m)16.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.09 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.33 | ||
| P/tB | N/A | ||
| EV/EBITDA | 2.8 |
EPS(TTM)-8.36
EYN/A
EPS(NY)-4.3
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS52.94
BVpS3.43
TBVpS-7.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.41% | ||
| ROE | -262.84% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.42% | ||
| FCFM | N/A |
ROA(3y)-46.66%
ROA(5y)-36.36%
ROE(3y)-176.86%
ROE(5y)-122.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.22%
GM growth 5Y-1.01%
F-Score5
Asset Turnover2.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 8.26% | ||
| Cap/Sales | 0.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.52 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | -4.55 |
F-Score5
WACC11.29%
ROIC/WACCN/A
Cap/Depr(3y)15.58%
Cap/Depr(5y)44.94%
Cap/Sales(3y)2.05%
Cap/Sales(5y)3.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.62%
EPS Next Y57.44%
EPS Next 2Y24.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.11%
Revenue growth 3Y-21.74%
Revenue growth 5Y-11.14%
Sales Q2Q%-39.72%
Revenue Next Year-41.79%
Revenue Next 2Y-25.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y58.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year119.12%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y80.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.48%
OCF growth 3YN/A
OCF growth 5Y-42.85%